<li>aliskiren<p>trimethoprim and aliskiren both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>amantadine<p>sulfamethoxazole increases levels of amantadine by decreasing elimination. Use Caution/Monitor. Coadministration may impair renal clearance of amantadine, resulting in higher plasma concentrations.<span><br><br></span>trimethoprim increases levels of amantadine by decreasing elimination. Use Caution/Monitor. Coadministration may impair renal clearance of amantadine, resulting in higher plasma concentrations.</p></li><li>amiloride<p>trimethoprim and amiloride both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>amiodarone<p>amiodarone will increase the level or effect of sulfamethoxazole by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>amiodarone<p>amiodarone will increase the level or effect of trimethoprim by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>amisulpride<p>amisulpride and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>amisulpride and sulfamethoxazole both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>amitriptyline<p>amitriptyline and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>amitriptyline and sulfamethoxazole both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>amoxapine<p>amoxapine and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>amoxapine and sulfamethoxazole both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>artemether/lumefantrine<p>sulfamethoxazole and artemether/lumefantrine both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>artemether/lumefantrine and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>aspirin<p>aspirin, sulfamethoxazole.
Either increases effects of the other by plasma protein binding competition. Use Caution/Monitor. Due to high protein binding capacity of both drugs, one may displace the other when coadministered leading to an enhanced effect of the displaced drug; risk is low with low dose aspirin.</p></li><li>bazedoxifene/conjugated estrogens<p>trimethoprim will decrease the level or effect of bazedoxifene/conjugated estrogens by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>aspirin/citric acid/sodium bicarbonate, sulfamethoxazole.
Either increases effects of the other by plasma protein binding competition. Use Caution/Monitor. Due to high protein binding capacity of both drugs, one may displace the other when coadministered leading to an enhanced effect of the displaced drug; risk is low with low dose aspirin.</p></li><li>bazedoxifene/conjugated estrogens<p>sulfamethoxazole will decrease the level or effect of bazedoxifene/conjugated estrogens by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.</p></li><li>benazepril<p>trimethoprim and benazepril both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>canagliflozin<p>trimethoprim and canagliflozin both increase  serum potassium. Use Caution/Monitor.</p></li><li>candesartan<p>trimethoprim and candesartan both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>captopril<p>trimethoprim and captopril both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>carvedilol<p>sulfamethoxazole will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>chlorpromazine<p>chlorpromazine and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>chlorpromazine and sulfamethoxazole both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>chlorpropamide<p>sulfamethoxazole increases levels of chlorpropamide by plasma protein binding competition. Use Caution/Monitor.</p></li><li>cimetidine<p>cimetidine will increase the level or effect of trimethoprim by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>cimetidine<p>cimetidine will increase the level or effect of sulfamethoxazole by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>clarithromycin<p>clarithromycin and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>clarithromycin and sulfamethoxazole both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>clomipramine<p>clomipramine and sulfamethoxazole both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>clomipramine and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>conjugated estrogens<p>sulfamethoxazole will decrease the level or effect of conjugated estrogens by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.<span><br><br></span>trimethoprim will decrease the level or effect of conjugated estrogens by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.</p></li><li>crofelemer<p>crofelemer increases levels of trimethoprim by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.</p></li><li>dapsone topical<p>sulfamethoxazole increases toxicity of dapsone topical by decreasing metabolism. Modify Therapy/Monitor Closely. May induce methemoglobinemia .</p></li><li>cyclosporine<p>trimethoprim and cyclosporine both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>dabrafenib<p>dabrafenib will decrease the level or effect of trimethoprim by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.</p></li><li>dapsone topical<p>trimethoprim increases toxicity of dapsone topical by decreasing metabolism. Modify Therapy/Monitor Closely. May induce methemoglobinemia .</p></li><li>dasatinib<p>sulfamethoxazole and dasatinib both increase  QTc interval. Use Caution/Monitor.</p></li><li>desipramine<p>desipramine and sulfamethoxazole both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>desipramine and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>digoxin<p>sulfamethoxazole will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>trimethoprim will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>sulfamethoxazole will increase the level or effect of digoxin by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.<span><br><br></span>digoxin will increase the level or effect of trimethoprim by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>dofetilide<p>dofetilide and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>sulfamethoxazole and dofetilide both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>sulfamethoxazole will increase the level or effect of dofetilide by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.<span><br><br></span>dofetilide will increase the level or effect of trimethoprim by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>dolasetron<p>dolasetron and trimethoprim both increase  QTc interval. Use Caution/Monitor.<span><br><br></span>sulfamethoxazole and dolasetron both increase  QTc interval. Use Caution/Monitor.</p></li><li>dosulepin<p>dosulepin and sulfamethoxazole both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>dosulepin and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>doxepin<p>doxepin and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>doxepin and sulfamethoxazole both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>dronabinol<p>sulfamethoxazole will increase the level or effect of dronabinol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Dronabinol is a CYP2C9 substrate.</p></li><li>dronedarone<p>dronedarone and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>dronedarone<p>sulfamethoxazole and dronedarone both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>droperidol<p>droperidol and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>sulfamethoxazole and droperidol both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>efavirenz<p>efavirenz will increase the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df increases levels of trimethoprim by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.<span><br><br></span>elvitegravir/cobicistat/emtricitabine/tenofovir df decreases levels of trimethoprim by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Elvitegravir is a moderate CYP2C9 inducer.</p></li><li>eltrombopag<p>sulfamethoxazole will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>eluxadoline<p>sulfamethoxazole increases levels of eluxadoline by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. As a precautionary measure due to incomplete information on the metabolism of eluxadoline, use caution when coadministered with strong CYP2C9/10 inhibitors.</p></li><li>enalapril<p>trimethoprim and enalapril both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>epinephrine<p>epinephrine and sulfamethoxazole both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>epinephrine and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>epinephrine racemic<p>epinephrine racemic and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>epinephrine racemic and sulfamethoxazole both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>eplerenone<p>trimethoprim and eplerenone both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>erythromycin base<p>sulfamethoxazole and erythromycin base both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>eprosartan<p>trimethoprim and eprosartan both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>erythromycin base<p>erythromycin base and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>erythromycin ethylsuccinate<p>erythromycin ethylsuccinate and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>sulfamethoxazole and erythromycin ethylsuccinate both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>erythromycin lactobionate<p>erythromycin lactobionate and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>sulfamethoxazole and erythromycin lactobionate both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>erythromycin stearate<p>sulfamethoxazole and erythromycin stearate both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>erythromycin stearate and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>estradiol<p>sulfamethoxazole will decrease the level or effect of estradiol by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.<span><br><br></span>trimethoprim will decrease the level or effect of estradiol by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.</p></li><li>estrogens conjugated synthetic<p>sulfamethoxazole will decrease the level or effect of estrogens conjugated synthetic by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.<span><br><br></span>trimethoprim will decrease the level or effect of estrogens conjugated synthetic by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.</p></li><li>estropipate<p>trimethoprim will decrease the level or effect of estropipate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.<span><br><br></span>sulfamethoxazole will decrease the level or effect of estropipate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.</p></li><li>ethinylestradiol<p>sulfamethoxazole will decrease the level or effect of ethinylestradiol by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.<span><br><br></span>trimethoprim will decrease the level or effect of ethinylestradiol by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.</p></li><li>ethotoin<p>sulfamethoxazole will increase the level or effect of ethotoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>flecainide<p>flecainide and trimethoprim both increase  QTc interval. Use Caution/Monitor.</p></li><li>etravirine<p>sulfamethoxazole will increase the level or effect of etravirine by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>flecainide<p>sulfamethoxazole and flecainide both increase  QTc interval. Use Caution/Monitor.</p></li><li>fluconazole<p>fluconazole and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>sulfamethoxazole and fluconazole both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>fluoxetine<p>fluoxetine will increase the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>fluoxetine and trimethoprim both increase  QTc interval. Use Caution/Monitor.</p></li><li>fluphenazine<p>fluphenazine and sulfamethoxazole both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>fluphenazine and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>fluvoxamine<p>fluvoxamine will increase the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>fluvoxamine and trimethoprim both increase  QTc interval. Use Caution/Monitor.<span><br><br></span>sulfamethoxazole and fluvoxamine both increase  QTc interval. Use Caution/Monitor.</p></li><li>formoterol<p>formoterol and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>sulfamethoxazole and formoterol both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>foscarnet<p>foscarnet and trimethoprim both increase  QTc interval. Use Caution/Monitor.<span><br><br></span>sulfamethoxazole and foscarnet both increase  QTc interval. Use Caution/Monitor.</p></li><li>fosinopril<p>trimethoprim and fosinopril both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>fosphenytoin<p>sulfamethoxazole will increase the level or effect of fosphenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>glimepiride<p>sulfamethoxazole increases levels of glimepiride by plasma protein binding competition. Use Caution/Monitor.</p></li><li>glipizide<p>sulfamethoxazole increases levels of glipizide by plasma protein binding competition. Use Caution/Monitor.</p></li><li>gliquidone<p>sulfamethoxazole increases levels of gliquidone by plasma protein binding competition. Use Caution/Monitor.</p></li><li>glucarpidase<p>glucarpidase will decrease the level or effect of sulfamethoxazole by  increasing metabolism. Modify Therapy/Monitor Closely. Leucorvorin, reduced folates, and folate antimetabolites are substrates for glucarpidase (hydrolyzes glutamate residue from folic acid and antifolates)<span><br><br></span>glucarpidase will decrease the level or effect of trimethoprim by  increasing metabolism. Modify Therapy/Monitor Closely. Leucorvorin, reduced folates, and folate antimetabolites are substrates for glucarpidase (hydrolyzes glutamate residue from folic acid and antifolates)</p></li><li>glyburide<p>sulfamethoxazole increases levels of glyburide by plasma protein binding competition. Use Caution/Monitor.<span><br><br></span>sulfamethoxazole increases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inhibitors may decrease glyburide metabolism.</p></li><li>haloperidol<p>haloperidol and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>haloperidol<p>sulfamethoxazole and haloperidol both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>iloperidone<p>iloperidone increases levels of trimethoprim by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.<span><br><br></span>iloperidone and trimethoprim both increase  QTc interval. Use Caution/Monitor.<span><br><br></span>sulfamethoxazole and iloperidone both increase  QTc interval. Use Caution/Monitor.</p></li><li>imatinib<p>imatinib will increase the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>imipramine<p>imipramine and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>imidapril<p>sulfamethoxazole, imidapril. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of hyperkalemia.</p></li><li>imipramine<p>imipramine and sulfamethoxazole both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>irbesartan<p>trimethoprim and irbesartan both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>itraconazole<p>itraconazole and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>sulfamethoxazole and itraconazole both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>ketoconazole<p>sulfamethoxazole and ketoconazole both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>ketoconazole and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>l-methylfolate<p>trimethoprim decreases effects of l-methylfolate by Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Folic acid antagonists may interfere with folic acid utilization.</p></li><li>lacosamide<p>sulfamethoxazole increases levels of lacosamide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP2C9 inhibitors.</p></li><li>lamivudine<p>trimethoprim increases effects of lamivudine by basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor. Potential for increased toxicity.</p></li><li>lapatinib<p>sulfamethoxazole and lapatinib both increase  QTc interval. Use Caution/Monitor.</p></li><li>lesinurad<p>sulfamethoxazole will increase the level or effect of lesinurad by  affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.</p></li><li>levofloxacin<p>sulfamethoxazole and levofloxacin both increase  QTc interval. Use Caution/Monitor.<span><br><br></span>levofloxacin and trimethoprim both increase  QTc interval. Use Caution/Monitor.</p></li><li>lisinopril<p>trimethoprim and lisinopril both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>lofepramine<p>lofepramine and sulfamethoxazole both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>lofepramine<p>lofepramine and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>losartan<p>trimethoprim and losartan both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.<span><br><br></span>sulfamethoxazole will increase the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.</p></li><li>lumacaftor/ivacaftor<p>lumacaftor/ivacaftor, trimethoprim. affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. In vitro studies suggest that lumacaftor may induce and ivacaftor may inhibit CYP2C9 substrates. .</p></li><li>lumefantrine<p>sulfamethoxazole and lumefantrine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>lumefantrine<p>lumefantrine and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>maprotiline<p>maprotiline and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>maprotiline and sulfamethoxazole both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>mestranol<p>trimethoprim will decrease the level or effect of mestranol by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.<span><br><br></span>sulfamethoxazole will decrease the level or effect of mestranol by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.</p></li><li>methadone<p>methadone and trimethoprim both increase  QTc interval. Use Caution/Monitor.<span><br><br></span>sulfamethoxazole and methadone both increase  QTc interval. Use Caution/Monitor.</p></li><li>methotrexate<p>trimethoprim increases toxicity of methotrexate by Other (see comment). Use Caution/Monitor. 
Comment: Trimethoprim may increase risk of methotrexate-induced bone marrow suppression and megaloblastic anemia. If this drug combination cannot be avoided, closely monitor for signs of hematologic toxicity.</p></li><li>methoxsalen<p>methoxsalen, sulfamethoxazole.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects.</p></li><li>metronidazole<p>metronidazole, sulfamethoxazole. Mechanism: decreasing metabolism. Use Caution/Monitor. Disulfiram like reaction.</p></li><li>mianserin<p>mianserin and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>mianserin and sulfamethoxazole both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>mipomersen<p>mipomersen, sulfamethoxazole.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs.</p></li><li>mitotane<p>mitotane decreases levels of trimethoprim by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.</p></li><li>moexipril<p>trimethoprim and moexipril both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>moxifloxacin<p>moxifloxacin and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>sulfamethoxazole and moxifloxacin both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>nateglinide<p>sulfamethoxazole will increase the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>sulfamethoxazole increases levels of nateglinide by plasma protein binding competition. Use Caution/Monitor.</p></li><li>nitisinone<p>nitisinone will increase the level or effect of trimethoprim by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index.</p></li><li>nilotinib<p>sulfamethoxazole and nilotinib both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>nortriptyline<p>nortriptyline and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>nortriptyline and sulfamethoxazole both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>octreotide<p>sulfamethoxazole and octreotide both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>octreotide and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>octreotide (antidote)<p>octreotide (antidote) and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>sulfamethoxazole and octreotide (antidote) both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>ofloxacin<p>sulfamethoxazole and ofloxacin both increase  QTc interval. Use Caution/Monitor.<span><br><br></span>ofloxacin and trimethoprim both increase  QTc interval. Use Caution/Monitor.</p></li><li>olmesartan<p>trimethoprim and olmesartan both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>ospemifene<p>sulfamethoxazole increases levels of ospemifene by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>sulfamethoxazole, ospemifene.
Either increases levels of the other by plasma protein binding competition. Modify Therapy/Monitor Closely.</p></li><li>paclitaxel<p>trimethoprim will increase the level or effect of paclitaxel by  Other (see comment). Use Caution/Monitor. Paclitaxel levels/toxicity may increase when coadministered with CYP2C8 inhibitors </p></li><li>paclitaxel protein bound<p>trimethoprim will increase the level or effect of paclitaxel protein bound by  Other (see comment). Use Caution/Monitor. Paclitaxel levels/toxicity may increase when coadministered with CYP2C8 inhibitors </p></li><li>paliperidone<p>sulfamethoxazole and paliperidone both increase  QTc interval. Use Caution/Monitor.<span><br><br></span>paliperidone and trimethoprim both increase  QTc interval. Use Caution/Monitor.</p></li><li>parecoxib<p>sulfamethoxazole will increase the level or effect of parecoxib by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>paroxetine<p>paroxetine and trimethoprim both increase  QTc interval. Use Caution/Monitor.</p></li><li>paroxetine<p>sulfamethoxazole and paroxetine both increase  QTc interval. Use Caution/Monitor.</p></li><li>pentamidine<p>trimethoprim and pentamidine both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>perindopril<p>trimethoprim and perindopril both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>perphenazine<p>perphenazine and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>perphenazine and sulfamethoxazole both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>phenytoin<p>sulfamethoxazole will increase the level or effect of phenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>posaconazole<p>posaconazole and trimethoprim both increase  QTc interval. Use Caution/Monitor.</p></li><li>porfimer<p>sulfamethoxazole, porfimer. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Enhanced photosensitivity.</p></li><li>posaconazole<p>sulfamethoxazole and posaconazole both increase  QTc interval. Use Caution/Monitor.</p></li><li>potassium acid phosphate<p>trimethoprim and potassium acid phosphate both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>potassium chloride<p>trimethoprim and potassium chloride both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>potassium citrate<p>trimethoprim and potassium citrate both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>potassium citrate/citric acid<p>trimethoprim and potassium citrate/citric acid both increase  serum potassium. Use Caution/Monitor.</p></li><li>pralatrexate<p>sulfamethoxazole increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor.</p></li><li>procainamide<p>procainamide will increase the level or effect of trimethoprim by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.<span><br><br></span>sulfamethoxazole will increase the level or effect of procainamide by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>prochlorperazine<p>prochlorperazine and sulfamethoxazole both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>prochlorperazine and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>promazine<p>promazine and sulfamethoxazole both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>promazine and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>promazine increases toxicity of sulfamethoxazole by unspecified interaction mechanism. Use Caution/Monitor. Enhanced myelosuppression.</p></li><li>promethazine<p>promethazine and sulfamethoxazole both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>promethazine and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>protriptyline<p>protriptyline and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>protriptyline and sulfamethoxazole both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>quinapril<p>trimethoprim and quinapril both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>quinidine<p>quinidine will increase the level or effect of sulfamethoxazole by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>quinidine<p>quinidine will increase the level or effect of trimethoprim by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>ramipril<p>trimethoprim and ramipril both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>ranolazine<p>ranolazine and trimethoprim both increase  QTc interval. Use Caution/Monitor.<span><br><br></span>sulfamethoxazole and ranolazine both increase  QTc interval. Use Caution/Monitor.</p></li><li>repaglinide<p>trimethoprim increases levels of repaglinide by decreasing metabolism. Use Caution/Monitor. Hepatic cytochrome P450 2C8.<span><br><br></span>sulfamethoxazole increases levels of repaglinide by plasma protein binding competition. Use Caution/Monitor.</p></li><li>risperidone<p>risperidone and trimethoprim both increase  QTc interval. Use Caution/Monitor.<span><br><br></span>sulfamethoxazole and risperidone both increase  QTc interval. Use Caution/Monitor.</p></li><li>sacubitril/valsartan<p>sacubitril/valsartan and trimethoprim both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>sertindole<p>sulfamethoxazole and sertindole both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>sertindole<p>sertindole and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>sodium picosulfate/magnesium oxide/anhydrous citric acid<p>sulfamethoxazole decreases effects of sodium picosulfate/magnesium oxide/anhydrous citric acid by altering metabolism. Use Caution/Monitor. Coadministration with antibiotics decreases efficacy by altering colonic bacterial flora needed to convert sodium picosulfate to active drug.<span><br><br></span>trimethoprim decreases effects of sodium picosulfate/magnesium oxide/anhydrous citric acid by altering metabolism. Use Caution/Monitor. Coadministration with antibiotics decreases efficacy by altering colonic bacterial flora needed to convert sodium picosulfate to active drug.</p></li><li>spironolactone<p>trimethoprim and spironolactone both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion.  May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>tamoxifen<p>sulfamethoxazole, tamoxifen. affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. CYP2C9/10 inhibition decreases tamoxifen metabolism to active metabolites.</p></li><li>sulfamethoxazole<p>sulfamethoxazole and trimethoprim both increase  QTc interval. Use Caution/Monitor.</p></li><li>telavancin<p>telavancin and trimethoprim both increase  QTc interval. Use Caution/Monitor.<span><br><br></span>sulfamethoxazole and telavancin both increase  QTc interval. Use Caution/Monitor.</p></li><li>telithromycin<p>sulfamethoxazole and telithromycin both increase  QTc interval. Use Caution/Monitor.<span><br><br></span>telithromycin and trimethoprim both increase  QTc interval. Use Caution/Monitor.</p></li><li>telmisartan<p>trimethoprim and telmisartan both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>thioridazine<p>thioridazine and sulfamethoxazole both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>thioridazine<p>thioridazine and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>tolazamide<p>sulfamethoxazole increases levels of tolazamide by plasma protein binding competition. Use Caution/Monitor.</p></li><li>tolbutamide<p>sulfamethoxazole increases levels of tolbutamide by plasma protein binding competition. Use Caution/Monitor.</p></li><li>trandolapril<p>trimethoprim and trandolapril both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>trazodone<p>trazodone and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>trazodone and sulfamethoxazole both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>triamterene<p>trimethoprim and triamterene both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>trifluoperazine<p>trifluoperazine and sulfamethoxazole both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>trifluoperazine<p>trifluoperazine and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>trimethoprim<p>sulfamethoxazole and trimethoprim both increase  QTc interval. Use Caution/Monitor.</p></li><li>trimipramine<p>trimipramine and trimethoprim both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>trimipramine and sulfamethoxazole both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>tropisetron<p>sulfamethoxazole and tropisetron both increase  QTc interval. Use Caution/Monitor.<span><br><br></span>trimethoprim and tropisetron both increase  QTc interval. Use Caution/Monitor.</p></li><li>valsartan<p>valsartan and trimethoprim both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>venlafaxine<p>sulfamethoxazole and venlafaxine both increase  QTc interval. Use Caution/Monitor.</p></li><li>venlafaxine<p>trimethoprim and venlafaxine both increase  QTc interval. Use Caution/Monitor.</p></li><li>voriconazole<p>trimethoprim and voriconazole both increase  QTc interval. Use Caution/Monitor.<span><br><br></span>sulfamethoxazole and voriconazole both increase  QTc interval. Use Caution/Monitor.</p></li><li>warfarin<p>sulfamethoxazole will increase the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>zidovudine<p>trimethoprim increases levels of zidovudine by decreasing renal clearance. Use Caution/Monitor. Potential for increased toxicity. .</p></li><li>ziprasidone<p>sulfamethoxazole and ziprasidone both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>trimethoprim and ziprasidone both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li>